Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible
reason for which is tumor microenvironment. Enhancer of zeste homolog 2 (EZH2) as a
epigenetic target for cancer therapy has attracted significant interest. The combination of
EZH2 inhibitors and programmed death-1 ligands/ transforming growth factor-β (PD-L1/TGFβ)
blockade may enhance the efficiency of immunotherapy.The primary objective of this study in
phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination
with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell
lymphomas. The phase Ⅱ stage of this study is to primarily evaluate the efficacy of SHR2554
plus SHR1701 and the epigenetic modulating effect of SHR2554.